CN107205933A - Raf抑制剂与aurora激酶抑制剂的组合 - Google Patents

Raf抑制剂与aurora激酶抑制剂的组合 Download PDF

Info

Publication number
CN107205933A
CN107205933A CN201580073520.8A CN201580073520A CN107205933A CN 107205933 A CN107205933 A CN 107205933A CN 201580073520 A CN201580073520 A CN 201580073520A CN 107205933 A CN107205933 A CN 107205933A
Authority
CN
China
Prior art keywords
day
cancer
raf
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580073520.8A
Other languages
English (en)
Chinese (zh)
Inventor
V·博泽恩
K·M·加尔文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN107205933A publication Critical patent/CN107205933A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201580073520.8A 2014-12-23 2015-12-22 Raf抑制剂与aurora激酶抑制剂的组合 Pending CN107205933A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096020P 2014-12-23 2014-12-23
US62/096,020 2014-12-23
PCT/US2015/067459 WO2016106357A1 (en) 2014-12-23 2015-12-22 Combination of raf inhibitors and aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
CN107205933A true CN107205933A (zh) 2017-09-26

Family

ID=56151529

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580073520.8A Pending CN107205933A (zh) 2014-12-23 2015-12-22 Raf抑制剂与aurora激酶抑制剂的组合

Country Status (6)

Country Link
US (1) US20180263979A1 (https=)
EP (1) EP3236948A4 (https=)
JP (1) JP2018502089A (https=)
CN (1) CN107205933A (https=)
CA (1) CA2972076A1 (https=)
WO (1) WO2016106357A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116004567A (zh) * 2022-12-07 2023-04-25 北京大学 极光激酶b基因k202突变及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081585A1 (en) 2016-10-28 2018-05-03 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof
CN111655228B (zh) 2017-05-03 2024-02-09 听治疗有限责任公司 预防和治疗听力损失的组合物和方法
WO2021108616A1 (en) * 2019-11-27 2021-06-03 Dot Therapeutics-1, Inc. Solid dispersion of pan-raf kinase inhibitor
AU2021376286A1 (en) * 2020-11-06 2023-06-22 Dana-Farber Cancer Institute, Inc. Raf inhibitor for treating low grade glioma

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018547A2 (en) * 2003-08-15 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
CN101056632A (zh) * 2004-11-09 2007-10-17 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
CN101218241A (zh) * 2005-05-16 2008-07-09 Irm责任有限公司 用作蛋白激酶抑制剂的吡咯并吡啶衍生物
CN101784545A (zh) * 2007-06-29 2010-07-21 苏尼西斯制药有限公司 用作raf激酶抑制剂的嘧啶衍生物
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103429238A (zh) * 2011-01-12 2013-12-04 勃林格殷格翰国际有限公司 极光激酶/mek双重抑制剂的抗癌疗法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747002B2 (en) * 1999-05-11 2004-06-08 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
CN104428001A (zh) * 2012-03-30 2015-03-18 武田药品工业有限公司 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
ES2686549T3 (es) * 2014-06-16 2018-10-18 Worldwide Innovative Network Método para seleccionar una triterapia personalizada para el tratamiento del cáncer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018547A2 (en) * 2003-08-15 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
CN101056632A (zh) * 2004-11-09 2007-10-17 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
CN101218241A (zh) * 2005-05-16 2008-07-09 Irm责任有限公司 用作蛋白激酶抑制剂的吡咯并吡啶衍生物
CN101784545A (zh) * 2007-06-29 2010-07-21 苏尼西斯制药有限公司 用作raf激酶抑制剂的嘧啶衍生物
CN103429238A (zh) * 2011-01-12 2013-12-04 勃林格殷格翰国际有限公司 极光激酶/mek双重抑制剂的抗癌疗法
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIDDLETON M ET AL.: ""First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma"", 《EUROPEAN JOURNAL OF CANCER》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116004567A (zh) * 2022-12-07 2023-04-25 北京大学 极光激酶b基因k202突变及其应用

Also Published As

Publication number Publication date
EP3236948A1 (en) 2017-11-01
EP3236948A4 (en) 2018-10-03
WO2016106357A1 (en) 2016-06-30
CA2972076A1 (en) 2016-06-30
WO2016106357A8 (en) 2017-06-01
US20180263979A1 (en) 2018-09-20
JP2018502089A (ja) 2018-01-25

Similar Documents

Publication Publication Date Title
JP2023100682A (ja) Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物
US10337004B2 (en) Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
CN107849615A (zh) 诊断和治疗癌症的方法
US20130231347A1 (en) Method of treatment with braf inhibitor
JP5908466B2 (ja) Ｒａｆ及びｍｅｋ阻害剤に対する耐性を与えるｍｅｋ１変異
JP6769962B2 (ja) 癌治療のためのキナーゼ阻害剤プロドラッグ
CN107205933A (zh) Raf抑制剂与aurora激酶抑制剂的组合
EA031190B1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
TW202039862A (zh) 受體酪氨酸激酶(kit)基因突變
JP5651125B2 (ja) Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
CN107405348B (zh) Raf抑制剂与紫杉烷的组合
KR20140096073A (ko) 혈관신생 억제제에 대한 반응성
GB2488028A (en) mTOR mutants as biomarkers for mTOR inhibitor treatment
US20220047574A1 (en) Crenolanib for treating pdgfr alpha mutated proliferative disorders
US20220047577A1 (en) Crenolanib for treating pdgfr alpha mutated proliferative disorders
WO2017066664A1 (en) Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2016106351A1 (en) Combination of raf inhibitors and mtor inhibitors
KR20140064924A (ko) 항-혈관신생 치료와 연관된 고혈압 위험성의 예측 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170926